LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.…
LENSAR Inc (LNSR) (Q3 2026) Earnings Call Highlights: Recurring Revenue Surges 17% as Margins ...
LENSAR (NASDAQ: LNSR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 150 employees.
The shares were at 4.460 USD on 20 November 2026, down 57.9% over 52 weeks. Its 52-week range is 4.300 USD to 12.94 USD: the price is 65.5% below the high and 3.7% above the low.
At a market capitalisation of 54.83M USD, it trades at 10.1 times trailing earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 60% for LNSR.
LENSAR reports return on equity of 131.7%, an operating margin of -33.3% and revenue down 1.3% year over year.
It holds more cash than debt, a net cash position of 10.44M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 11.00 USD is 146.6% above the current price. The next earnings report is expected on 25 February 2027.